New treatments to extend life for multiple myeloma patients

February 10, 2017 by From Mayo Clinic News Network, Mayo Clinic News Network
Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0

Multiple myeloma is a cancer of the plasma cells that reside inside bone marrow. Plasma cells produce certain proteins that build up the immune system. In abnormal quantities, these proteins damage the body and compromise the immune system.

Historically, patients with did not survive more than a couple of years after diagnosis. Now, patients with this type of cancer are living more than three times as long thanks to new, more effective treatments.

"We are now able to diagnose and treat myeloma earlier, before it starts damaging the body, so that it may be controlled effectively and any irreversible damage to the body may be delayed significantly," says Dr. Sikander Ailawadhi, a hematologist/oncologist at Mayo Clinic Cancer Center in Jacksonville, Fla.

In 2015, within a span of two weeks, the U.S. Food and Drug Administration approved three new drugs to treat multiple myeloma.

"It was unprecedented to have these drugs approved within such a short span of time for the treatment of a disease which is considered incurable," says Ailawadhi. But, with the excellent treatment options now available - and centers that specialize in the treatment of this condition – he adds most patients can achieve remission and have had an improvement in survival.

"We can almost guarantee some degree of response to every single patient who walks through the doors for treatment with newly diagnosed myeloma," he adds.

"Some of the most exciting things are the development of new drugs," explains Ailawadhi. "Specifically, using currently available drugs to see what drives resistance of the , isolating those pathways and then developing that can specifically target those resistance mechanisms."

More drugs are on the horizon, Ailawadhi says, noting that there are many active clinical trials available to patients through the Hematologic Malignancies Program, which conducts blood and cancer research.

Currently, there are more than 50 active clinical trials available at Mayo Clinic.

Explore further: Study shows that choice of medical center impacts life expectancy of multiple myeloma patients

6 shares

Related Stories

Study shows that choice of medical center impacts life expectancy of multiple myeloma patients

October 26, 2016
People diagnosed with multiple myeloma are more likely to live longer if they are treated at a medical center that sees many patients with this blood cancer. Mayo Clinic researchers published these findings today in the Journal ...

Empliciti approved for multiple myeloma

November 30, 2015
(HealthDay)—Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat the blood cancer multiple myeloma. The drug is only approved for patients who ...

Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma

April 15, 2016
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to ...

New drug class gives hope for better treatments for incurable myeloma

August 8, 2016
Australian researchers have discovered that a new class of anti-cancer agents may be effective in treating multiple myeloma, an incurable bone marrow cancer.

Research suggests common blood cancer could be prevented before it develops

July 11, 2016
Researchers from the University of Birmingham and hospitals across the West Midlands have revealed how a common symptomless condition can develop into the blood cancer myeloma.

Early treatment may prevent progression to multiple myeloma

December 5, 2016
Early intervention with an immunotherapy-based drug combination may prevent progression of high-risk "smoldering" multiple myeloma to the full-blown disease, according to researchers from Dana-Farber Cancer Institute.

Recommended for you

Two ways cancer resists treatment are actually connected, with one activating the other

December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting ...

Vaccine, checkpoint drugs combination shows promise for pancreatic cancers

December 18, 2018
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people ...

HPV discovery raises hope for new cervical cancer treatments

December 18, 2018
Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus (HPV) that could lead to new treatments for cervical cancer and other cancers caused by the virus.

Researchers identify ways breast cancer avoids immune system detection

December 18, 2018
Recent breakthroughs in immunotherapy are making a huge difference in treating some forms of cancer, especially metastatic cancer. But breast cancer has proven a tricky foe for this new therapy, and an interdisciplinary team ...

Metal chemotherapy drugs boost the impact of immunotherapy in cancer

December 18, 2018
Due to their powerful tumour-killing effect, metal-based chemotherapies are frequently used in cancer treatment. However, it was hitherto assumed that they damaged the immune system, because of their cytotoxic (cell-damaging) ...

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.